Results 321 to 330 of about 9,870,305 (401)

Clinical pharmacology considerations for first-in-human clinical trials for enzyme replacement therapy. [PDF]

open access: yesJ Inherit Metab Dis
Stern S   +7 more
europepmc   +1 more source

Evolution of Ocular Organ‐On‐Chip Systems for Disease Modelling and Drug Testing: Where are We Now?

open access: yesAdvanced Therapeutics, EarlyView.
The rise in ophthalmic diseases due to aging, screen use, and environmental factors has driven demand for better ocular models. Traditional systems fall short, encouraging the development of organ‐on‐chip devices. These microfluidic platforms replicate eye tissue architecture, enable drug screening, and simulate ocular diseases.
Sara Trujillo
wiley   +1 more source

SMYD3 Promotes Immune Evasion in Clear Cell Renal Cell Carcinoma via SREBP1‐Mediated Transactivation of CD47

open access: yesAdvanced Science, EarlyView.
Cancer cell‐intrinsic SMYD3 orchestrates an immunosuppressive microenvironment and impairs the response to PD‐1 blockade by reprogramming immune cells landscape in the tumor microenvironment of clear cell renal cell carcinoma (ccRCC). The immunomodulatory function of SMYD3 is mediated via the SREBP1/CD47 pathway.
Zhengfang Liu   +14 more
wiley   +1 more source

Lecithin Alleviates Memory Deficits and Muscle Attenuation in Chinese Older Adults and SAMP8 Mice

open access: yesAdvanced Science, EarlyView.
This study opens a new avenue for safeguarding cognition and muscle health, averting disability in older age, and treating age‐related pathologies through lecithin supplementation. It serves as a promising nonpharmacological intervention for the crosstalk of muscle and cognition.
Xianyun Wang   +16 more
wiley   +1 more source

Lycium barbarum Glycopeptide Alleviates Neomycin‐Induced Ototoxicity by Inhibiting Tryptophan Hydroxylase‐Mediated Serotonin Biosynthesis

open access: yesAdvanced Science, EarlyView.
Lycium barbarum glycopeptide (LBGP), which is further extracted from Lycium barbarum polysaccharides, exhibits significant protective effects against neomycin‐induced hearing dysfunction including oxidative stress in cochlea and loss of key cells in cochlea.
Yunhao Wu   +12 more
wiley   +1 more source

Advances in Microfluidic Cochlea‐On‐A‐Chip

open access: yesAdvanced Science, EarlyView.
This review systematically examines diverse cell sources for inner ear organoids and outlines stepwise induction protocols. Furthermore, it discusses current applications and prospective developments of cochlea‐on‐a‐chip technologies in areas such as deafness modeling, mechanistic studies, and drug evaluation, with particular focus on gene‐therapy drug
Tian Shen   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy